GYRE THERAPEUTICS INC (GYRE) Stock Income Statement
NASDAQ:GYRE - Nasdaq - US4037831033 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 105.76M | 113.45M | 790.00K | 7.34M | 20.95M | |||
| Minority Interest Expense | -5.81M | -7.45M | N/A | N/A | N/A | |||
| Cost Of Goods | 3.88M | 4.64M | 800.00K | 7.38M | 9.16M | |||
| Gross Profit | 101.87M | 108.81M | 0.00 | -40.00K | 11.79M | |||
| Operating Expenses | 85.64M | 89.60M | 29.41M | 87.85M | 68.36M | |||
| Research and Development | 12.02M | 13.78M | 12.44M | 68.89M | 52.18M | |||
| Selling, General, and Administrative Expenses | 73.62M | 75.82M | 16.97M | 18.96M | 16.18M | |||
| Operating Income | 16.23M | 19.21M | -29.41M | -87.89M | -56.57M | |||
| Interest Income/Expense | 1.55M | 1.04M | 540.00K | 40.00K | 560.00K | |||
| Other Income/Expense | 5.51M | -10.78M | 0.00 | -80.00K | 570.00K | |||
| Non Recurring Items | -66.00K | -86.44M | 20.98M | N/A | -800.00K | |||
| Income Before Taxes | 23.22M | -76.97M | -7.89M | -87.93M | -56.24M | |||
| Income Tax | 5.32M | 8.52M | 350.00K | N/A | N/A | |||
| Net Income | 12.09M | -92.93M | -8.24M | -87.93M | -56.24M | |||
| EBITDA | 17.78M | 20.29M | -29.21M | -87.59M | -56.47M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 0.12 | -1.41 | -3.92 | -43.10 | -43.93 | |||
| Non GAAP EPS | N/A | N/A | N/A | -2.87 | -2.83 | |||
| Statistics | ||||||||
| Gross Profit Margin | 96.33% | 95.91% | N/A | -0.54% | 56.28% | |||
| Profit Margin | 11.43% | -81.92% | -1043.04% | -1197.96% | -268.45% | |||
| Operating Profit Margin | 15.35% | 16.94% | -3722.78% | -1197.41% | -270.02% | |||
All data in USD